[(10R,13R,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] (2S)-2-aminopropanoate;2,2,2-trifluoroacetic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [(10R,13R,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] (2S)-2-aminopropanoate;2,2,2-trifluoroacetic acid
• 化学式: C34H53F6NO6
• 分子量: 685.8
• InChiKey: ZGSQTGUDCZDWFD-JLXFCWNCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.55
• 重原子数：
  47
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  127
• 氢给体数：
  3
• 氢受体数：
  13

文献信息

• POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS
  申请人：Molecular Transfer, Inc.

  公开号：EP2912045A2

  公开（公告）日：2015-09-02
• TRANSFECTION COMPLEXES AND METHODS OF USING THE SAME
  申请人：Molecular Transfer, Inc.

  公开号：EP3341027A2

  公开（公告）日：2018-07-04
• PLANT VIRUS MOVEMENT PROTEINS AND METHODS OF USING THE SAME
  申请人：Molecular Transfer, Inc.

  公开号：EP3423438A1

  公开（公告）日：2019-01-09
• [EN] POLYCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS<br/>[FR] PHOSPHOLIPIDES MÉTHYLIQUES POLYCATIONIQUES POUR UNE LIBÉRATION AMÉLIORÉE D'ACIDES NUCLÉIQUES DANS DES CELLULES EUCARYOTES
  申请人：MOLECULAR TRANSFER INC

  公开号：WO2014070687A2

  公开（公告）日：2014-05-08

  New cationic lipids are provided that are useful for delivering macromolecules, such as nucleic acids, into eukaryotic cells. The lipids can be used alone, in combination with other lipids and/or in combination with other transfection enhancing reagents to prepare transfection complexes.
• [EN] TRANSFECTION COMPLEXES AND METHODS OF USING THE SAME<br/>[FR] COMPLEXES DE TRANSFECTION ET LEURS PROCÉDÉS D'UTILISATION
  申请人：MOLECULAR TRANSFER INC

  公开号：WO2017040335A2

  公开（公告）日：2017-03-09

  Disclosed herein are transfection complexes comprising at least one cell surface ligand; at least one helper lipid component; and a transfection enhancer. Also disclosed are pharmaceutical compositions comprising the disclosed transfection complexes, and a pharmaceutically acceptable carrier. Further, disclosed are methods of transfecting a cell, the method comprising the steps of: obtaining a transfection complex as disclosed; and contacting a cell with the transfection complex.